TYK Medicines, Inc. Class H

As of December 31, 2025, TYK Medicines, Inc. Class H carries a market capitalization of 4.98B, placing it among publicly traded companies globally. Its enterprise value stands at 4.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TYK Medicines, Inc. Class H's next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2025, TYK Medicines, Inc. Class H has 380.07M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, TYK Medicines, Inc. Class H maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, TYK Medicines, Inc. Class H's stock has declined approximately 78.45% over the past 52 weeks. The 50-day moving average sits at 4.66, while the 200-day moving average is 8.54.

As of December 31, 2025, TYK Medicines, Inc. Class H holds 352.22M in cash and equivalents against 170.06M in total debt, resulting in a net debt position of -202.97M. Total book value stands at 319.03M, with working capital of 148.31M providing operational flexibility.